

10/61/90
S. U. S. P. O.

06-20-01

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
481.06S. P. O.
09/8845
09/8845
09/8845
09/8845

06/19/01

Re Application Of: LISLE W. GEORGE, ET AL.

Serial No.

N/A

Filing Date

JUNE 19, 2001

Examiner

N/A

Group Art Unit

N/A

Title: **MORAXELLA BOVIS CYTOTOXIN, CYTOTOXIN GENE, ANTIBODIES AND VACCINES
FOR PREVENTION AND TREATMENT OF MORAXELLA BOVIS INFECTIONS**

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

1. UTILITY PATENT APPLICATION TRANSMITTAL;
2. SPECIFICATION HAVING 69 PAGES; INFORMATION DRAWINGS HAVING 19 SHEETS;
3. UNSIGNED DECLARATION AND POWER OF ATTORNEY FORM;
4. CHECK IN THE AMOUNT OF \$712.00; AND
5. RETURN POSTCARD.

in the above identified application.

No additional fee is required.
 A check in the amount of \$712.00 is attached.
 The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 16-1331 as described below. A duplicate copy of this sheet is enclosed.
 Charge the amount of
 Credit any overpayment.
 Charge any additional fee required.


Signature

Dated: JUNE 19, 2001

HANA VERNY (REG. NO. 30,518)
PETERS, VERNY, JONES & BIKSA LLP
385 SHERMAN AVENUE, SUITE 6
PALO ALTO, CA 94306
TELEPHONE: (650)324-1677
FACSIMILE: (650)324-1678

I certify that this document and fee is being deposited on JUNE 19, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Signature of Person Mailing Correspondence

HANA VERNY (REG. NO. 30,518)

Typed or Printed Name of Person Mailing Correspondence

CC:

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

481.06

Total Pages in this Submission

98

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**MORAXELLA BOVIS CYTOTOXIN, CYTOTOXIN GENE, ANTIBODIES AND VACCINES
FOR PREVENTION AND TREATMENT OF MORAXELLA BOVIS INFECTIONS**

and invented by:

LISLE W. GEORGE, ET AL.

JC903 U.S. PRO
09/884696
06/19/01

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below

2. Specification having 69 pages and including the following:
 - a. Descriptive Title of the Invention
 - b. Cross References to Related Applications (*if applicable*)
 - c. Statement Regarding Federally-sponsored Research/Development (*if applicable*)
 - d. Reference to Microfiche Appendix (*if applicable*)
 - e. Background of the Invention
 - f. Brief Summary of the Invention
 - g. Brief Description of the Drawings (*if drawings filed*)
 - h. Detailed Description
 - i. Claim(s) as Classified Below
 - j. Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
481.06

Total Pages in this Submission
98

Application Elements (Continued)

3. Drawing(s) (*when necessary as prescribed by 35 USC 113*)
a. Formal b. Informal Number of Sheets 19

4. Oath or Declaration
a. Newly executed (*original or copy*) Unexecuted
b. Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
c. With Power of Attorney Without Power of Attorney
d. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (*usable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.

6. Computer Program in Microfiche

7. Genetic Sequence Submission (*if applicable, all must be included*)
a. Paper Copy
b. Computer Readable Copy
c. Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. Assignment Papers (*cover sheet & documents*)

9. 37 CFR 3.73(b) Statement (*when there is an assignee*)

10. English Translation Document (*if applicable*)

11. Information Disclosure Statement/PTO-1449 Copies of IDS Citations

12. Preliminary Amendment

13. Acknowledgment postcard

14. Certificate of Mailing
 First Class Express Mail (*Specify Label No.:* EL852965475US)

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
481.06

Total Pages in this Submission
98

Accompanying Application Parts (Continued)

15. Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. Small Entity Statement(s) - Specify Number of Statements Submitted: _____
17. Additional Enclosures *(please identify below):*

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
 481.06

Total Pages in this Submission
 98

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	33	- 20 =	13	x \$9.00	\$117.00
Indep. Claims	9	- 3 =	6	x \$40.00	\$240.00
Multiple Dependent Claims (check if applicable)	<input type="checkbox"/>				\$0.00
				BASIC FEE	\$355.00
OTHER FEE (specify purpose)					\$0.00
				TOTAL FILING FEE	\$712.00

A check in the amount of \$712.00 to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge and credit Deposit Account No. 16-1331 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____ as filing fee.

Credit any overpayment.

Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: JUNE 19, 2001



Signature

HANA VERNY (REG. NO. 30,518)
 PETERS, VERNY, JONES & BIKSA LLP
 385 SHERMAN AVENUE, SUITE 6
 PALO ALTO, CA 94306
 TELEPHONE: (650)324-1677
 FACSIMILE: (650)324-1678

cc: